MaxCyte Reports Q2 2026 Earnings with Revenue Decline but Reduced Net Loss
MaxCyte (MXCT) reported second-quarter financial results for 2026, showing a total revenue of $7.3 million—a 15% year-over-year decline driven by lower core and SPL program-related revenues due to discontinued partner programs and timing variability in instrument sales. Despite the drop in revenue, the company reduced its net loss from $12.4 million to $8.9 million compared to Q2 2025, largely attributed to cost efficiency measures implemented earlier that year. The firm ended the quarter with cash and investments of $141.9 million and no debt on its balance sheet. It also continued a share repurchase program authorized by the board, having spent $5.5 million so far out of an allocated $10 million. MaxCyte provided full-year revenue guidance between $30 million to $32 million, with core revenue expected at $25–$27 million and SPL-related revenue projected at around $5 million. The company highlighted a strong pipeline of 30 partner license agreements and noted clinical progress in its programs. However, it acknowledged ongoing risks from program discontinuations and inventory adjustments by key customers.
Tickers: $MXCT